1.1999
price down icon0.42%   -0.0051
after-market Handel nachbörslich: 1.20 0.000100 +0.01%
loading
Schlusskurs vom Vortag:
$1.205
Offen:
$1.23
24-Stunden-Volumen:
7,920
Relative Volume:
0.12
Marktkapitalisierung:
$2.43M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-9.32M
KGV:
-0.0944
EPS:
-12.7107
Netto-Cashflow:
$-7.30M
1W Leistung:
+6.20%
1M Leistung:
-17.82%
6M Leistung:
-38.47%
1J Leistung:
-77.85%
1-Tages-Spanne:
Value
$1.19
$1.23
1-Wochen-Bereich:
Value
$1.05
$1.28
52-Wochen-Spanne:
Value
$0.952
$6.4485

Tharimmune Inc Stock (THAR) Company Profile

Name
Firmenname
Tharimmune Inc
Name
Telefon
302-743-2995
Name
Adresse
1200 ROUTE 22 EAST, BRIDGEWATER
Name
Mitarbeiter
3
Name
Twitter
Name
Nächster Verdiensttermin
2024-08-05
Name
Neueste SEC-Einreichungen
Name
THAR's Discussions on Twitter

Vergleichen Sie THAR mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
THAR
Tharimmune Inc
1.1999 2.43M 0 -9.32M -7.30M -12.71
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
493.84 122.76B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
602.64 61.38B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
614.76 36.37B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
251.56 30.12B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
244.90 24.70B 3.81B -644.79M -669.77M -6.24

Tharimmune Inc Aktie (THAR) Neueste Nachrichten

pulisher
10:28 AM

Tharimmune announces board retirements ahead of annual meeting By Investing.com - Investing.com South Africa

10:28 AM
pulisher
04:41 AM

Press Release Distribution & PR Platform - ACCESS Newswire

04:41 AM
pulisher
Apr 15, 2025

Tharimmune (THAR) Expands Board with New Appointment | THAR Stoc - GuruFocus

Apr 15, 2025
pulisher
Apr 15, 2025

Tharimmune Strengthens Strategic Leadership with the Appointment of Vincent LoPriore to its Board of Directors - standard-journal.com

Apr 15, 2025
pulisher
Apr 15, 2025

Healthcare Investment Expert Managing $150M Portfolio Strengthens Tharimmune's Strategic Leadership - Stock Titan

Apr 15, 2025
pulisher
Apr 08, 2025

Tharimmune reports data on new biparatopic biologics - BioWorld MedTech

Apr 08, 2025
pulisher
Apr 07, 2025

THAR stock touches 52-week low at $1.12 amid sharp annual decline By Investing.com - Investing.com South Africa

Apr 07, 2025
pulisher
Apr 07, 2025

THAR stock touches 52-week low at $1.12 amid sharp annual decline - Investing.com Australia

Apr 07, 2025
pulisher
Apr 07, 2025

Tharimmune Reports Preclinical Data for Dual-Target Biologics - MarketScreener

Apr 07, 2025
pulisher
Apr 07, 2025

Tharimmune Announces Positive Data With Novel Biparatopic PD-1/VEGF & Multispecific HER2/HER3 Biologics Leveraging Proprietary Epiclick(TM) Technology - MarketScreener

Apr 07, 2025
pulisher
Apr 07, 2025

Tharimmune Announces Positive Data with Novel Biparatopic PD-1/VEGF and Multispecific HER2/HER3 Biologics Leveraging Proprietary EpiClick(TM) Technology - Weatherford Democrat

Apr 07, 2025
pulisher
Apr 07, 2025

Breakthrough Cancer Drug Shows Superior Design: Tharimmune's Dual-Target Biologic Outperforms Competition - Stock Titan

Apr 07, 2025
pulisher
Apr 05, 2025

Tharimmune receives Nasdaq non-compliance notice - Investing.com Australia

Apr 05, 2025
pulisher
Apr 05, 2025

Tharimmune receives Nasdaq non-compliance notice By Investing.com - Investing.com Canada

Apr 05, 2025
pulisher
Apr 03, 2025

Tharimmune, Inc. (NASDAQ:THAR) Short Interest Update - Defense World

Apr 03, 2025
pulisher
Apr 02, 2025

Virtu Financial LLC Makes New Investment in Tharimmune, Inc. (NASDAQ:THAR) - Defense World

Apr 02, 2025
pulisher
Mar 31, 2025

THAR stock touches 52-week low at $1.2 amid sharp annual decline By Investing.com - Investing.com South Africa

Mar 31, 2025
pulisher
Mar 31, 2025

Jayud Global Logistics Ltd (JYD): What Makes The Stock Good? - Marketing Sentinel

Mar 31, 2025
pulisher
Mar 31, 2025

THAR stock touches 52-week low at $1.2 amid sharp annual decline - Investing.com

Mar 31, 2025
pulisher
Mar 31, 2025

Tharimmune Says FDA Requires No Additional Trials of TH104 Against Opioid Exposure - MarketScreener

Mar 31, 2025
pulisher
Mar 31, 2025

FDA greenlights Tharimmune’s drug application pathway - Investing.com India

Mar 31, 2025
pulisher
Mar 31, 2025

Tharimmune Announces Positive FDA Feedback on NDA Path for TH104 for Prophylaxis of Respiratory and/or CNS Depression for Ultrapotent Opioid Exposure - Weatherford Democrat

Mar 31, 2025
pulisher
Mar 31, 2025

FDA Fast-Tracks Tharimmune's Revolutionary Opioid Defense Drug: No Clinical Trials Needed - Stock Titan

Mar 31, 2025
pulisher
Mar 24, 2025

12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga

Mar 24, 2025
pulisher
Mar 24, 2025

Tharimmune Announces Positive Results for Novel Oral Monoclonal Antibody TH023 Targeting Tumor Necrosis Factor-alpha - Weatherford Democrat

Mar 24, 2025
pulisher
Mar 24, 2025

Game-Changing Oral Alternative to Injectable Antibody Achieves Key Milestone - Stock Titan

Mar 24, 2025
pulisher
Mar 05, 2025

Tharimmune leverages Epiclick platform to expand pipeline - BioWorld Online

Mar 05, 2025
pulisher
Mar 04, 2025

Hillstream Biopharma stock hits 52-week low at $1.36 - Investing.com

Mar 04, 2025
pulisher
Mar 04, 2025

Tharimmune Announces Positive Target Engagement with Novel Biparatopic PD-1/VEGF and Multispecific HER2/HER3 Biologics Leveraging Proprietary EpiClick Technology - Markets Insider

Mar 04, 2025
pulisher
Mar 04, 2025

Tharimmune unveils novel cancer treatment HS1940 - Investing.com India

Mar 04, 2025
pulisher
Mar 04, 2025

Tharimmune unveils novel cancer treatment HS1940 By Investing.com - Investing.com South Africa

Mar 04, 2025
pulisher
Mar 01, 2025

Short Interest in Tharimmune, Inc. (NASDAQ:THAR) Declines By 58.6% - Defense World

Mar 01, 2025
pulisher
Mar 01, 2025

Short Interest in Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) Expands By 148.7% - Defense World

Mar 01, 2025
pulisher
Feb 27, 2025

Tharimmune appoints new CFO following resignation By Investing.com - Investing.com Canada

Feb 27, 2025
pulisher
Feb 27, 2025

Tharimmune Says Thomas Hess Resigns As CFO -February 27, 2025 at 05:34 pm EST - Marketscreener.com

Feb 27, 2025
pulisher
Feb 27, 2025

Tharimmune Says Thomas Hess Resigns As CFO - TradingView

Feb 27, 2025
pulisher
Feb 27, 2025

Tharimmune appoints new CFO following resignation - Investing.com

Feb 27, 2025
pulisher
Feb 25, 2025

Hillstream Biopharma stock hits 52-week low at $1.83 By Investing.com - Investing.com Canada

Feb 25, 2025
pulisher
Feb 24, 2025

Hillstream Biopharma stock hits 52-week low at $1.83 - Investing.com

Feb 24, 2025
pulisher
Feb 23, 2025

Financial Analysis: ObsEva (NASDAQ:OBSV) & Tharimmune (NASDAQ:THAR) - Defense World

Feb 23, 2025
pulisher
Feb 22, 2025

Comparing Tharimmune (NASDAQ:THAR) and Phio Pharmaceuticals (NASDAQ:PHIO) - Defense World

Feb 22, 2025
pulisher
Feb 19, 2025

Tharimmune (NASDAQ:THAR) and Cara Therapeutics (NASDAQ:CARA) Head-To-Head Review - Armenian Reporter

Feb 19, 2025
pulisher
Feb 17, 2025

Comparing Cara Therapeutics (NASDAQ:CARA) & Tharimmune (NASDAQ:THAR) - Defense World

Feb 17, 2025
pulisher
Feb 13, 2025

Larchmont broker accused of years-long insider trading scheme - Westfair Communications

Feb 13, 2025
pulisher
Feb 07, 2025

Tharimmune (NASDAQ:THAR) Trading 3% Higher – Should You Buy? - Defense World

Feb 07, 2025

Finanzdaten der Tharimmune Inc-Aktie (THAR)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$20.59
price up icon 0.24%
$69.69
price up icon 1.06%
$32.20
price up icon 0.53%
$23.46
price down icon 36.06%
$102.02
price down icon 15.36%
biotechnology ONC
$244.90
price down icon 4.40%
Kapitalisierung:     |  Volumen (24h):